Cardiovascular Drug Could Deliver Esophageal Cancer Treatments

Cardiovascular Drug Could Deliver Esophageal Cancer Treatments

Phase II study results from French biotech Cerenis Therapeutics show that a drug initially developed to treat cardiovascular disease could be used to deliver treatments for esophageal cancer.

The drug, CER-001, mimics a member of a lipoprotein family called HDL, which reacts with a number of different receptors that are highly expressed in some cancers. In the Phase II trial, patients with esophageal cancer were first given a radiolabeled version of CER-001. The patients then underwent a PET-CT scan to see whether the drug targeted esophageal tumors.

Preliminary results from five patients showed the drug increased the signal from esophageal tumors by 50% in all five patients. Based on these findings, Cerenis believes CER-001 could help deliver esophageal cancer treatments to specific cellular targets. According to Cerenis, they are the first company with clinical data on HDL-based drug delivery.

ADVERTISEMENT

Because HDL also transports cholesterol around the body, CER-001 was first developed as a cardiovascular drug. However, Cerenis failed two Phase II studies last year and in 2014 testing the same drug for treating a cardiovascular disease called post-acute coronary syndrome.

Lipoproteins like CER-001 are biodegradable, which makes them well-suited as drug-delivery compounds. Nonetheless, current lipoprotein drug delivery methods have mainly reduced treatment toxicity without increasing efficacy. While the Cerenis’ Phase II imaging results suggest CER-001 could lead to more target-specific treatments for esophageal cancer, we still have to see how it holds up when combined with a drug that actually attacks tumor tissue.


Image by Kateryna Kon/Shutterstock

Previous post

Oxford Biotech Finds First Epigenetic Biomarkers to Diagnose ALS

Next post

Blow Your Own Horn Over Your New Biotech Job!

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.